公开(公告)号：EP3212616A1

公开(公告)日：2017-09-06

申请号：EP15854604.4

申请日：2015-10-26

申请人： Merck Sharp & Dohme Corp.

发明人： PASTERNAK, Alexander ,  DONG, Shuzhi ,  GU, Xin ,  JIANG, Jinlong ,  SHI, Zhi-Cai ,  WALSH, Shawn P. ,  WU, Zhicai ,  YU, Yang ,  FERGUSON, Ronald II ,  GUO, Zhiqiang ,  FRIE, Jessica ,  SUZUKI, Takao ,  BLIZZARD, Timothy A. ,  FU, Qinghong ,  VANGELDER, Kelsey F.

IPC分类号： C07D211/28 ,  C07D211/62

CPC分类号： C07D498/10 ,  A61K31/401 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/4422 ,  A61K31/444 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/551 ,  A61K31/585 ,  A61K31/675 ,  A61P3/14 ,  A61P7/10 ,  A61P9/12 ,  C07D471/10 ,  C07D497/10 ,  A61K2300/00

摘要： The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

公开(公告)号：EP3145915A1

公开(公告)日：2017-03-29

申请号：EP15795833.1

申请日：2015-05-19

申请人： Merck Sharp & Dohme Corp.

发明人： BIFU, Tesfaye ,  BIJU, Purakkattle ,  BLIZZARD, Timothy A. ,  CHEN, Zhengxia ,  CLEMENTS, Matthew J. ,  CUI, Mingxiang ,  FRIE, Jessica L. ,  HAGMANN, William K. ,  HU, Bin ,  JOSIEN, Hubert ,  NAIR, Anilkumar G. ,  PLUMMER, Christopher W. ,  ZHU, Cheng

IPC分类号： C07D221/16 ,  C07D401/12 ,  C07D405/12 ,  A61K31/438 ,  A61K31/415 ,  A61P3/10

CPC分类号： C07D221/16 ,  A61K31/192 ,  A61K31/366 ,  A61K31/397 ,  A61K31/435 ,  A61K31/438 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/4985 ,  A61K31/538 ,  A61K31/55 ,  A61K45/06 ,  C07C61/39 ,  C07C2602/08 ,  C07C2603/12 ,  C07D215/14 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  A61K2300/00

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：EP3097101A1

公开(公告)日：2016-11-30

申请号：EP15740935.0

申请日：2015-01-20

申请人： Merck Sharp & Dohme Corp.

发明人： BERGER, Richard ,  BLIZZARD, Timothy A. ,  CAMPBELL, Brian T. ,  CHEN, Helen Y. ,  DEBENHAM, John S. ,  DEWNANI, Sunita V. ,  DUBOIS, Byron ,  GUDE, Candido ,  GUO, Zhiqiang ,  HARPER, Bart ,  HU, Zhiyong ,  LIN, Songnian ,  LIU, Ping ,  WANG, Ming ,  UJJAINWALLA, Feroze ,  XU, Jiayi ,  XU, Libo ,  ZHANG, Rui

IPC分类号： C07D471/04

CPC分类号： C07D413/14 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/14 ,  C07D471/04

摘要： The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

摘要翻译： 式I的化合物作为MGAT2抑制剂，可用于预防，治疗或作为高脂血症，糖尿病和肥胖症的补救剂。